FDA Approves New Treatment for FOP Bone Condition
The FDA approved the monoclonal antibody garetosmab in August 2026 to treat fibrodysplasia ossificans progressiva.
Updated on Oct. 29, 2026 in Arthritis
In August 2026, the Food and Drug Administration approved the drug garetosmab for the treatment of fibrodysplasia ossificans progressiva (FOP). This rare condition causes muscles, tendons, and connective tissue to turn into bone.
Why it matters
The approval provides a new medical intervention for a rare, progressive condition that has historically lacked therapeutic options. It marks the third treatment option now available for patients suffering from this debilitating disease.
Garetosmab, a monoclonal antibody manufactured by Regeneron, reduces new abnormal bone formation by 90 percent in patients. It joins zilurgisertib and palovarotene as the three approved treatments for the disease.
The players
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Regeneron
This biotechnology company focuses on the discovery, invention, development, manufacture, and commercialization of medicines for serious diseases.
Jordyn Bugarin
A 22-year-old patient who has lived with the symptoms of fibrodysplasia ossificans progressiva since early childhood.
The details
Garetosmab acts as a monoclonal antibody to slow the process where soft tissues like tendons and muscles calcify into bone. It provides an alternative to existing therapies, including zilurgisertib, which functions by inhibiting the ALK2 protein.
Timeline
The mutated gene causing the condition was discovered in 2006.
Jordyn Bugarin's grandmother identified FOP symptoms in 2006.
The FDA approved garetosmab in August 2026.
Health Landscape
This drug approval represents a significant scientific milestone occurring 20 years after the 2006 discovery of the mutated gene that causes the condition. It signals a move toward targeted therapies that address the underlying biological mechanisms of rare genetic diseases.
Patients diagnosed with fibrodysplasia ossificans progressiva now have an additional monoclonal antibody treatment option to help reduce new bone formation. This provides doctors with greater flexibility when determining appropriate therapeutic regimens for those managing the condition.
The takeaway
The arrival of garetosmab increases the total number of approved FOP treatments to three, offering hope for slowing disease progression. Patients should consult with specialized medical providers to discuss how this new drug compares to existing therapies like zilurgisertib.
Further reading
Learn more about advancements in managing Arthritis and related musculoskeletal conditions.
Source note: This article includes information reported by The New York Times.
